| Debt - Margin Loan Facility (Details) - USD ($) shares in Millions, $ in Millions | 3 Months Ended | |||
|---|---|---|---|---|
| Jun. 26, 2024 | Mar. 31, 2025 | Dec. 31, 2024 | Mar. 31, 2024 | |
| Line of credit | ||||
| Debt disclosures | ||||
| Carrying value | $ 454 | $ 447 | ||
| SPV | Margin loan facility | ||||
| Debt disclosures | ||||
| Carrying value | 790 | $ 790 | ||
| Remaining borrowing capacity | $ 1,150 | |||
| Number of business days prior to the maturity date | 5 days | |||
| Basis spread on variable rate | 1.875% | |||
| Debt Instrument, Variable Interest Rate, Type [Extensible Enumeration] | SOFR | |||
| Commitment Fee Percentage | 0.50% | |||
| Interest rate | 6.20% | 7.20% | ||
| SPV | Margin loan facility | Charter | Asset pledged as collateral | ||||
| Debt disclosures | ||||
| Shares owned | 19.1 | |||
| Value of pledged collateral | $ 7,000 | |||
| SPV | Revolving credit facility | ||||
| Debt disclosures | ||||
| Maximum borrowing capacity | $ 1,150 | |||
| SPV | Uncommitted incremental term loan facility | ||||
| Debt disclosures | ||||
| Maximum borrowing capacity | 200 | |||
| SPV | Term loan | ||||
| Debt disclosures | ||||
| Carrying value | $ 1,150 | 
| X | ||||||||||
| 
- Definition Amount, after unamortized (discount) premium, of long-term debt. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations. No definition available. 
 | 
| X | ||||||||||
| 
- Definition The number of business days prior to the maturity date where the revolving loan facility is not available. No definition available. 
 | 
| X | ||||||||||
| 
- Definition Debt Instrument, Unused Borrowing Capacity Fee, Percent No definition available. 
 | 
| X | ||||||||||
| 
- Definition Percentage points added to the reference rate to compute the variable rate on the debt instrument. No definition available. 
 | 
| X | ||||||||||
| 
- Definition Effective interest rate for the funds borrowed under the debt agreement considering interest compounding and original issue discount or premium. Reference 1: http://www.xbrl.org/2003/role/exampleRef 
 | 
| X | ||||||||||
| 
- Definition Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. Reference 1: http://www.xbrl.org/2003/role/exampleRef 
 | 
| X | ||||||||||
| 
- Definition Amount of unused borrowing capacity under the long-term financing arrangement that is available to the entity as of the balance sheet date. Reference 1: http://www.xbrl.org/2003/role/disclosureRef 
 | 
| X | ||||||||||
| 
- Definition Indicates type of variable interest rate on debt instrument. Reference 1: http://www.xbrl.org/2003/role/disclosureRef 
 | 
| X | ||||||||||
| 
- Definition The aggregate fair value as of the balance sheet date of financial instruments and other positions owned by the entity including: (1) mortgages, mortgage-backed and asset backed securities; (2) US government and agency obligations; (3) state and municipal government obligations; (4) other sovereign government debt; (5) corporate obligations; (6) corporate equities; (7) principal investments; (8) derivative contracts; and (9) physical commodities. Includes both pledged and unpledged holdings. Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef 
 | 
| X | ||||||||||
| 
- Definition Number of shares of investment owned. Reference 1: http://www.xbrl.org/2003/role/disclosureRef 
 | 
| X | ||||||||||
| 
- Definition Maximum borrowing capacity under the credit facility without consideration of any current restrictions on the amount that could be borrowed or the amounts currently outstanding under the facility. Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef 
 | 
| X | ||||||||||
| 
- Details 
 | 
| X | ||||||||||
| 
- Details 
 | 
| X | ||||||||||
| 
- Details 
 | 
| X | ||||||||||
| 
- Details 
 | 
| X | ||||||||||
| 
- Details 
 | 
| X | ||||||||||
| 
- Details 
 | 
| X | ||||||||||
| 
- Details 
 | 
| X | ||||||||||
| 
- Details 
 |